Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference

Key Points

• Esperion reported 38% year‑over‑year revenue growth and said a recent guideline update gives its bempedoic acid therapies multiple Class 1A recommendations, which management expects will validate NEXLETOL/NEXLIZET positioning and expand the combination lipid‑lowering market.
• The company acquired Corstasis and Enbumyst (a nasally delivered bumetanide approved in September 2025) and plans customer‑facing field staff by May 1 with a full commercial launch by September; the deal carries $75 million upfront, up to $180 million in sales‑based milestones and a 15% royalty, financed via monetized Japanese royalties and a term‑loan expansion.
• Esperion will train and deploy its 155 sales reps to support the Enbumyst and lipid franchises while advancing a triple‑combination LDL therapy aimed for 2027 and a PSC program expected to enter the clinic this year.

Esperion Therapeutics NASDAQ: ESPR outlined its commercial progress and strategic priorities at Needham & Company’s 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and guideline tailwinds for its cholesterol franchise, and the recent acquisition of Corstasis Therapeutics and its heart failure product Enbumyst.

President and CEO Sheldon Koenig said the company has made significant strides over the past year, pointing to “38% year-over-year growth in revenue” and “34% growth year-over-year in TRPEs.” He also noted that Esperion’s partner in Japan, described as “the third largest market in the world,” launched bempedoic acid in November and is “off to a great start.”

Corstasis acquisition brings Enbumyst heart failure product

Koenig and CFO Ben Halladay discussed Esperion’s acquisition of Corstasis Therapeutics, which brought Enbumyst, a nasally delivered loop diuretic intended to help congestive heart failure patients offload fluid at home. Koenig described the administration as similar to other nasal products: “Essentially what the patient does is they squirt this in their nose, and it allows them to go to the bathroom.”

Koenig framed the opportunity around hospital readmissions, saying that “one in four” of the nearly 7 million congestive heart failure patients are readmitted within 30 days, and that hospitals and physicians are judged—and in some cases financially impacted—by readmission rates. He added that “almost 80% of patients who leave the hospital after going in to be diuresed, they’re still what is called wet,” suggesting an ongoing need for additional fluid removal after discharge.

Enbumyst uses bumetanide, which Koenig said is “40x more potent than furosemide.” He argued that during heart failure episodes patients can develop “gut edema,” making them resistant to oral diuretics, and positioned Enbumyst as a tool to avoid emergency department visits while helping patients return to oral therapy.

• Regulatory status: Koenig confirmed Enbumyst was approved in September 2025.
• Commercial timing: Koenig said Esperion will have “customer-facing folks in the field by May the 1st” and expects to be “fully launched by September.”
• Initial positioning: The company is focusing first on office-based use when patients have symptoms, with a hospital discharge protocol strategy considered a later phase.

Halladay said Corstasis previously had “around 10 people out there discussing the product” and had laid groundwork through conference presence, early case studies, and initial payer discussions. Esperion expects to expand that effort. Halladay noted Esperion currently has “155 sales reps,” and said “we will have all of them trained and marketing this come September,” along with additional IDN-focused personnel prior to then.

Deal terms and financing

Halladay described the transaction as $75 million upfront, with “$180 million in sales-based milestones” and “a 15% royalty on worldwide net sales.” He added that none of the milestones are expected in “the next year or two,” with at least one regulatory milestone “a few years out.”

To finance the upfront payment, Halladay said Esperion used “a combination of monetizing our Japanese royalties” and expanding its term loan facility by $25 million. Koenig added that Athyrium Capital and HealthCare Royalty supported the financing and conducted diligence, calling their involvement “another feather in the cap of why this deal makes sense.”

Guideline update seen as major catalyst for NEXLETOL and NEXLIZET

Koenig said updated treatment guidelines—released roughly three weeks before the conference—were a “real big deal” because they provide independent validation of where Esperion’s products fit in lipid-lowering therapy. He said Esperion received “three Class A1 recommendations or 1A recommendations” and “four other recommendations,” while noting the document is “142 pages” and complex. He added that bempedoic acid is mentioned “almost 90 times,” and that the guideline writers included a dedicated section on the CLEAR Outcomes study.

Koenig emphasized that in the guidelines, Esperion’s therapy is presented as an “equal choice,” rather than being positioned before or after other therapies. He attributed the placement to the CLEAR Outcomes data presented in April 2023 and a subsequent label in April 2024. Koenig said the company has already deployed field materials to help physicians map the recommendations to specific patient profiles, and noted that Esperion has “six” medical science liaisons engaging with regional thought leaders.

Koenig also argued that a return to LDL target goals should expand the overall market for combination lipid-lowering therapy. He said physicians must now pursue LDL targets such as “75 or 55 mg per deciliter,” and that “the days of just using one drug are over.” Halladay added that the guidelines reinforced Esperion’s commercial focus on “primary prevention” and “statin intolerance,” noting that statin intolerance was recognized as a category in the guidelines for the first time, according to his comments.

Commercial execution, seasonality, and ex-U.S. progress

Management said it continues to see first-quarter seasonality, with added disruption from winter storms. Koenig said distribution and patient access were affected for “over two weeks,” but he reported that March showed a “significant pickup” and said the company expects momentum to carry forward.

Internationally, Halladay cautioned that Japan has statutory first-year prescribing constraints managed through 14-day renewals, limiting adherence early on. He said the strategy is to prioritize prescriber breadth so that after the first 12 months, the launch can accelerate. He also said Esperion’s European partner Daiichi Sankyo launched France in the first quarter and achieved “very favorable reimbursement,” which he characterized as meaningful given the market size.

On generic litigation, Halladay said there are “four” remaining parties, with “three…acting as a consortium,” and said Esperion is “optimistic” about reaching positive resolutions. Koenig reiterated confidence in the strength of Esperion’s patents.

Pipeline updates: triple combo and PSC program

Koenig said Esperion’s triple-combination product is now primarily awaiting stability data, with bioequivalence already achieved under a 505(b)(2) strategy. He said the therapy could reach “LDL upwards of 70%” lowering and that Esperion hopes to be on the market in 2027. Halladay said Daiichi Sankyo has not provided specific European timing but is “very excited” about the product.

Koenig also said the company’s primary sclerosing cholangitis (PSC) program remains on track to enter the clinic this year and described it as a potential disease-modifying approach: “This isn’t a drug that treats symptoms. This is a drug that goes to the injury in the liver and treats it.”

On manufacturing, Halladay said Esperion expects a phased tech transfer through the year, with gross margins improving by year-end as production aligns more closely with typical small-molecule biotech economics.

Koenig closed by emphasizing execution against stated goals and described the Corstasis deal as expanding Esperion’s longer-term opportunity under its “Vision 2040” framework.

About Esperion Therapeutics NASDAQ: ESPR

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.